Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Permira Snaps Up Cambrex in $2.4 Billion Deal

Shares of Cambrex Corp. were up more than 46 percent in trading after the company announced an agreement to be acquired by an affiliate of the Permira funds for $60 per share, totaling $2.4 billion.

Read More »

Adaptive Biotechnologies to Triple Seattle Footprint with New HQ

Adaptive Biotechnologies announced plans to lease a new corporate headquarters, tripling the company’s footprint in Seattle.

Read More »

Israel’s Teva Pharm profit falls less than expected, CFO to leave

Teva Pharmaceutical Industries reported a smaller-than-expected drop in second-quarter 2019 profit and said the chief financial officer was leaving the company.

Read More »

NIH Researcher Launches LUCA Biologics

Cambridge, Massachusetts-based LUCA Biologics launched and will focus on women’s health, beginning with urinary tract infections (UTI).

Read More »

EVERSANA opens offices in Singapore & Mumbai

EVERSANA, a leading independent provider of global commercial services to the life science industry, announced the rapid expansion of the company’s Asia Pacific business with the addition of two new offices in Singapore and Mumbai.

Read More »

GSK ends development of Ebola vaccine, hands work to U.S. institute

GlaxoSmithKline transferred the company’s work on developing three potential vaccines against the Ebola and Marburg viruses.

Read More »

Sosei and Takeda Ink $1.2+ Billion Deal

Sosei inked a strategic multi-target partnership with Takeda to find, develop and commercialize small molecules and biologics that modulate G protein-coupled receptor (GPCR) targets.

Read More »

Fast Company recognizes Klick on Inaugural List of 50 Best Workplaces for Innovators

Klick Inc. named to Fast Company’s first-ever list of Best Workplaces for Innovators, honoring businesses and organizations that demonstrate a deep commitment to encouraging innovation at all levels.

Read More »

Pfizer’s Rivipansel Fails to Meet Primary and Secondary Efficacy Endpoints in Sickle Cell Trial

Pfizer announced that the company’s Phase III RESET clinical trial evaluating rivipansel in sickle cell disease (SCD) failed to meet the study’s primary and key secondary efficacy endpoints.

Read More »

RAPT Therapeutics Postpones $86 Million IPO

South San Francisco-based RAPT Therapeutics is postponing an initial public offering to raise $86 million via selling 5 million shares at $14 to $16 per share.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom